UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat breast cancer in early trial
Disease control TerminatedThis phase I trial is testing a new drug called ASTX727 (a combination of decitabine and cedazuridine) alongside standard chemotherapy (paclitaxel) and immunotherapy (pembrolizumab) for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The st…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise against tough breast cancer
Disease control OngoingThis study tests a combination of two drugs, eribulin and copanlisib, in people with metastatic triple-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combo can slow tumor growth better than eribulin alone. About 24 …
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC